Shares of YM BioSciences Inc. soared 68% Tuesday on nearly 11 times the normal daily volume. Analysts said they weren't sure what was driving the stock higher, and the company said in a statement that its policy is not to comment on unusual market activity.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to BOTTOM of this page for free stock alerts, or visit our site.
YM BioSciences Inc. (YM BioSciences) is engaged in the licensing and commercialization of drug products and technologies from original research. The Company is advancing two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer, and AeroLEF, an inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain. Its products in clinical development target solid tumors, including colorectal, prostate, head and neck, breast, pancreatic, esophageal, specific types of brain tumors and acute pain, including cancer pain. The Company’s product portfolio includes Nimotuzumab, Tesmilifene (DDPE) and AeroLEF.
About Stock Einstein
StockEinstein uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
Disclaimer: Full disclaimer at http://StockEinsteain.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinsteain, nor any of its affiliates are registered investment advisors or broker dealers.
Thank you for your interest in Findit News. A member of the Findit News team will contact you soon to show you how you can take your marketing to the next level with press releases on Findit.
